Display options
Share it on

JRSM Cardiovasc Dis. 2017 Sep 12;6:2048004017729984. doi: 10.1177/2048004017729984. eCollection 2017.

Galectin-3, a marker of cardiac remodeling, is inversely related to serum levels of marine omega-3 fatty acids. A cross-sectional study.

JRSM cardiovascular disease

K Laake, I Seljeflot, E B Schmidt, P Myhre, A Tveit, J Norseth, H Arnesen, S Solheim

Affiliations

  1. Oslo University Hospital, Ullevål, Norway.
  2. Faculty of Medicine, University of Oslo, Norway.
  3. Center for Heart Failure Research, University of Oslo, Norway.
  4. Aalborg University Hospital, Aalborg, Denmark.
  5. Akershus University Hospital, Lørenskog, Norway.
  6. Vestre Viken Hospital Trust, Bærum Hospital, Rud, Norway.

PMID: 28932392 PMCID: PMC5600299 DOI: 10.1177/2048004017729984

Abstract

OBJECTIVE: Marine polyunsaturated n-3 fatty acids (n-3 PUFA) may have cardioprotective effects and beneficial influence on the fibrotic process. We evaluated the associations between serum marine n-3 PUFA and selected biomarkers of fibrosis and cardiac remodeling in elderly patients with acute myocardial infarction.

SETTING: From the ongoing OMega-3 fatty acids in Elderly patients with Myocardial Infarction (OMEMI) trial, 299 patients were investigated. Soluble ST2 (sST2), Galectin-3 (Gal-3) and the serum content of major marine n-3 and n-6 PUFA were analyzed 2-8 weeks after the index acute myocardial infarction.

RESULTS: Gal-3 was inversely correlated to eicosapentaenoic acid (r = -.120,

CONCLUSIONS: The associations between the marine n-3 PUFA and levels of Gal-3 indicate beneficial effects of n-3 PUFA on cardiac remodeling in an elderly population with acute myocardial infarction.

Keywords: Elderly; acute myocardial infarction; cardiac remodeling; heart failure; marine n-3 fatty acids

References

  1. Ann Med. 2011 Feb;43(1):60-8 - PubMed
  2. N Engl J Med. 2011 Jun 23;364(25):2439-50 - PubMed
  3. Am J Pathol. 2008 Feb;172(2):288-98 - PubMed
  4. Circulation. 2009 Jun 23;119(24):3110-7 - PubMed
  5. J Am Coll Cardiol. 2011 Feb 15;57(7):870-9 - PubMed
  6. Am J Respir Crit Care Med. 2016 Jul 1;194(1):77-83 - PubMed
  7. Clin Chim Acta. 2016 Jan 15;452:50-7 - PubMed
  8. J Exp Med. 1998 Mar 2;187(5):787-94 - PubMed
  9. J Lipids. 2016;2016:4945720 - PubMed
  10. Circulation. 2011 Feb 15;123(6):584-93 - PubMed
  11. Circ Heart Fail. 2012 Jan;5(1):72-8 - PubMed
  12. J Am Coll Cardiol. 2008 Oct 28;52(18):1458-65 - PubMed
  13. Oxid Med Cell Longev. 2016;2016:9618092 - PubMed
  14. Br J Nutr. 2000 Nov;84(5):781-7 - PubMed
  15. Circulation. 2004 May 11;109 (18):2186-90 - PubMed
  16. Lancet. 1989 Sep 30;2(8666):757-61 - PubMed
  17. Eur J Pharmacol. 2015 Sep 15;763(Pt A):115-21 - PubMed
  18. J Exp Med. 2014 Jul 28;211(8):1673-87 - PubMed
  19. Lancet. 1999 Aug 7;354(9177):447-55 - PubMed
  20. J Clin Invest. 2007 Jun;117(6):1538-49 - PubMed
  21. Clin Chem. 2012 Jan;58(1):257-66 - PubMed
  22. J Biol Chem. 1957 May;226(1):497-509 - PubMed
  23. Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):433-40 - PubMed
  24. Lancet. 2008 Oct 4;372(9645):1223-30 - PubMed
  25. Nat Rev Cardiol. 2014 May;11(5):255-65 - PubMed
  26. BMC Geriatr. 2014 Jun 13;14:74 - PubMed
  27. Am J Cardiol. 2015 Apr 2;115(7 Suppl):3B-7B - PubMed
  28. Eur J Prev Cardiol. 2015 Sep;22(9):1096-110 - PubMed
  29. Circulation. 2000 Jun 27;101(25):2981-8 - PubMed

Publication Types